3'4'7-trihydroxyflavone inhibits RANKL-induced osteoclast formation via NFATc1

Pharmazie

Volumn 70, Issue 10, 2015, Pages 661-667

  Kang, Ju Hee ^a   Lee, Juhyun ^a   Moon, Miran ^a   Yim, Mijung ^a  

^a Sookmyung Women's University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

3'4'7 TRIHYDROXYFLAVONE; ADENOSINE TRIPHOSPHATASE; B LYMPHOCYTE INDUCED MATURATION PROTEIN 1; CALCITONIN RECEPTOR; CATHEPSIN K; DENDRITIC CELL SPECIFIC TRANSMEMBRANE PROTEIN; FLAVONE DERIVATIVE; INTERFERON CONSENSUS SEQUENCE BINDING PROTEIN; MEMBRANE PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE P38; NUCLEAR FACTOR OF ACTIVATED T CELL C1; OSTEOCLAST DIFFERENTIATION FACTOR; PROTEIN C FOS; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG; V ATPASE V0 SUBUNIT D2; 3',4',7-TRIHYDROXYFLAVONE; FLAVONOID; NFATC1 PROTEIN, MOUSE; PRDM1 PROTEIN, MOUSE; TNFSF11 PROTEIN, MOUSE; TRANSCRIPTION FACTOR NFAT;

ANIMAL CELL; ARTICLE; BONE MARROW DERIVED MACROPHAGE; CELL DIFFERENTIATION; CELL VIABILITY; DENTIN SLICE; ENZYME PHOSPHORYLATION; GENE EXPRESSION; IN VITRO STUDY; MALE; MARKER GENE; MOUSE; MTT ASSAY; NONHUMAN; OSTEOCLAST; OSTEOCLASTOGENESIS; OSTEOLYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TISSUE DIFFERENTIATION; ANIMAL; ANTAGONISTS AND INHIBITORS; BONE MARROW; DRUG EFFECTS; INSTITUTE FOR CANCER RESEARCH MOUSE; METABOLISM; PREVENTION AND CONTROL;

ANIMALS; BONE MARROW; BONE RESORPTION; FLAVONOIDS; MICE; MICE, INBRED ICR; NFATC TRANSCRIPTION FACTORS; OSTEOCLASTS; P38 MITOGEN-ACTIVATED PROTEIN KINASES; RANK LIGAND; TRANSCRIPTION FACTORS;

EID: 84953343350     PISSN: 00317144     EISSN: None     Source Type: Journal    
DOI: 10.1691/ph.2015.5575     Document Type: Article

References (64)

1. Akiyama T, Dass CR, Choong PF (2008) Novel therapeutic strategy for osteosarcoma targeting osteoclast differentiation, bone-resorbing activity, and apoptosis pathway. Mol Cancer Ther 7: 3461-3469.
2. Aliprantis AO, Ueki Y, Sulyanto R, Park A, Sigrist KS, Sharma SM, Ostrowski MC, Olsen BR, Glimcher LH (2008)NFATc1 in mice represses osteoprotegerin during osteoclastogenesis and dissociates systemic osteopenia from inflammation in cherubism. J Clin Invest 118: 3775-3789.
3. Ang ES, Yang X, Chen H, Liu Q, Zheng MH, Xu J (2011) Naringin abrogates osteoclastogenesis and bone resorption via the inhibition of RANKL-induced NF-KB and ERK activation. FEBS Lett 585: 2755-2762.
4. Asagiri M, Sato K, Usami T, Ochi S, Nishina H, Yoshida H, Morita I, Wagner EF, Mak TW, Serfling E, Takayanagi H (2005) Autoamplification of NFATc1 expression determines its essential role in bone homeostasis. J Exp Med 202: 1261-1269.
5. Asagiri M, Takayanagi H (2007) The molecular underatanding of osteoclast differentiation. Bone 40: 251-264.
6. Bickoff EM, Witt SC, Livingston AL (1965) 3', 4', 7-trihydroxyflavone in alfalfa. J Pharm Sci 54:1555.
7. Boyle WJ, Simonet WS, Lacey DL (2003) Osteoclast differentiation and activation. Nature 423: 337-342.
8. Chamsukasi P, Choi JS, Woo WS (1981) 3', 4', 7-trihydroxyflavone in Albizzia julibrissin. Arch Pharm Res 4: 129-131.
9. Chiba H, Urehara M, Wu J, Wang X, Masuyama R, Suzuki K, Kanazawa K, Ishimi Y (2003) Hesperidin, a Citrus flavonoid, inhibits bone loss and decreases serum and hepatic lipids in ovariectomized mice. J Nutr 133: 1892-1897.
10. Dacquin R, Davey RA, Laplace C, Lavasseur R, Morris HA, Goldring SR, Gebre-Medhin S, Galson DL, Zajac JD, Karsenty G (2004) Amylin inhibits bone resorption while the calcitonin receptor controls bone formation in vivo. J Cell Biol 164: 509-514.
11. Darnay BG, Ni J, Moore PA, Aqqarwal BB (1999) Activation of NF-kappaB by RANK requires tumor necrosis factor receptor-associated factor (TRAF) 6 and NF-kappaB-inducing kinase. Identification of a novel TRAF6 interaction motif. J Biol Chem 274: 7724-7731.
12. Davey RA, Turner A, McManus JF, Chiu WS, Tjahyono F, Moore AJ, Atkins GJ, Anderson PH, Ma C, Glatt V, MacLean HE, Vincent C, Bouxsein M, Morris HA, Findlay DM, Zajac JD (2008) Calcitonin receptor plays a physiological role to protect against hypercalcemia in mice. J Bone Miner Res 23: 1182-1193.
13. Dou C, Li J, Kang F, Cao Z, Yang X, Jiang H, Yang B, Xiang J, Xu J, Dong S (2014) Dual effect of cyanidin on RANKL-induced differentiation and fusion of osteoclasts. J Cell Physiol DOI:10.1002/jcp.24916.
14. Feng X (2005) RANKing intracellular signaling in osteoclasts. IUBMB Life 57: 389-395.
15. Gabor M (1979) Anti-inflammatory substances of plant origin. In: Vane JR and Ferreira SH, (eds.) Handbook of Experimental Pharmacolgy, Anti-Inflammatory Drugs, Chapter 39. Springer-Verlag, New York, p. 698-739.
16. Garcia Palacio V, Robinson LJ, Borysenko CW, Lehmann T, Kalla SE, Blair HC (2005) Negative regulation of RANKL-induced osteoclastic differentiation in RAW264.7 Cells by estrogen and phytoestrogens. J Biol Chem 280: 13720-13727.
17. Goto T, Haqiwara K, Shirai N, Yoshida K, Haqiwara H (2015) Apigenin inhibits osteoblastogenesis and osteoclastogenesis and prevents bone loss in ovariectomized mice. Cytotechnology 67: 357-365.
18. Ha H, Kwak HB, Lee SW, Jin HM, Kim HM, Kim HH, Lee ZH (2004) Reactive oxygen species mediate RANK signaling in osteoclasts. Exp Cell Res 301: 119-127.
19. Han J, Ye M, Xu M, Wun J, Wang B, Guo D (2007) Characterization of flavonoids in the traditional Chinese herbal medicine-Huangqin by liquid chromatography coupled with electrospray ionization mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 848: 355-362.
20. Hsu H, Lacey DL, Dunstan CR, Solovyev I, Colombero A, Timms E, Tan H-L, Elliott G, Kelley MJ, Sarosi I, Wang L, Xia X-Z, Elliott R, Chiu L, Black T, Scully S, Capparelli C, Morony S, Shimamoto G, Bass MB, Boyle WJ (1999) Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand. Proc Natl Acad Sci USA 96: 3540-3545.
21. Huang H, Chang EJ, Ryu J, Lee ZH, Lee Y, Kim HH (2006) Induction of c-Fos and NFATc1 during RANKL-stimulated osteoclast differentiation is mediated by the p38 signaling pathway. Biochem Biophys Res Commun 351: 99-105.
22. Jung MJ, Chung HY, Kang SS, Choi JH, Bae KS, Choi JS (2003) Antioxidant activity from the stem bark Albizzia julibrissin. Arch Pharm Res 26: 458-462.
23. Kim K, Kim JH, Lee J, Jin HM, Kook H, Kim KK, Lee SY, Kim N (2007) MafB negatively regulates RANKL-mediated osteoclast differentiation. Blood 109:;1; 3253-3259.
24. Kim K, Lee SH, Ha Kim J, Choi Y, Kim N (2008) NFATc1 induces osteoclast fusion via up-regulation of Atp6v0d2 and the dendritic cell-specific transmembrane protein (DC-STAMP). Mol Endocrinol 22: 176-185.
25. 2+ oscillations essential for osteoclastogenesis. J Biol Chem 285: 6913-6921.
26. Kim TH, Jung JW, Ha BG, Hong JM, Park EK, Kim HJ, Kim SY (2011) The effects of luteolin on osteoclast differentiation, function in vitro and ovariectomy-induced bone loss. J Nutr Biochem 22: 8-15.
27. Lafont AG, Wang YF, Chen GD, Liao BK, Tseng YC, Huang CJ, Hwang PP (2011) Involvement of calcitonin and its receptor in the control of calcium-regulating genes and calcium homeostasis in zebrafish (Danio rerio). J Bone Miner Res 26: 1072-1083.
28. Lean JM, Davies JT, Fuller K, Jagger CJ, Kirstein B, Partington GA, Urry ZL, Chambers TJ (2003) A crucial role for thiol antioxidants in estrogen-deficiency bone loss. J Clin Invest 112: 915-923.
29. Lee NK, Choi YG, Baik JY, Han SY, Jeong DW, Bae YS, Kim N, Lee SY (2005) A crucial role for reactive oxygen species in RANKL-induced osteoclast differentiation. Blood 106: 852-859.
30. Lee SH, Rho J, Jeong D, Sul JY, Kim T, Kim N, Kang JS, Miyamoto T, Suda T, Lee SK, Pignolo RJ, Koczon-Jaremko B, Lorenzo J, Choi Y (2006) v-ATPase V0 subunit d2-deficient mice exhibit impaired osteoclast fusion and increased bone formation. Nat Med 12: 1403-1409.
31. Lindeman Jan HN, Hanemaaijer R, Mulder A, Dijkstra PD, Szuhai K, Bromme D, Verheijen JH, Hogendoorn PC (2004) Cathepsin K is the principal protease in giant cell tumor of bone. Am J Pathol 165:593-600.
32. Livingston AL, Bickoff EM (1964) Identification of 3', 4', 7-trihydroxyflavone in ladino clover. J Pharm Sci 53: 1557.
33. Li X, Udagawa N, Itoh K, Suda K, Murase Y, Nishihara T, Suta T, Takahashi N (2002) p38 MAPK-mediated signals are required for inducing osteo-clast differentiation but not for osteoclast function. Endocrinology 143: 3105-3113.
34. ManolagasSC (2010) From estrogen-centric to aging and oxidative stress. a revised perspective of the pathogenesis of osteoporosis. Endocr Rev 31: 266-300.
35. Matsuo K, Galson DL, Zhao C, Peng L, Laplace C, Wang KZ, Bachler MA, Amano H, Aburatani H, Ishikawa H, Wagner EF (2004) Nuclear Factor of Activated T-cells (NFAT) rescues osteoclastogenesis in precursors lacking c-Fos. J Biol Chem 279: 26475-26480.
36. Matsumoto M, Sudo T, Saito T, Osada H, Tsujimoto M (2000) Involvement of p38 mitogen-activated protein kinase signaling pathway in osteoclastogenesis mediated by Receptor Activator of NF-KB Ligand (RANKL). J Biol Chem 275: 31155-31161.
37. Miksicek RJ (1993) Commonly occurring plant flavonoids have estrogenic activity. Mol Pharmacol 44: 37-43.
38. Nakamura H, Ukai T, Yoshimura A, Kozuka Y, Yoshioka H, Yoshinaga Y, Abe Y, Hara Y (2010) Green tea catechin inhibits lipopolysaccharide-induced bone resorption in vivo. J Periodont Res 45: 23-30.
39. Nishikawa K, Nakashima T, Hayashi M, Fukunaga T, Kato S, Kodama T, Takahashi S, Calame K, Takayanagi H (2010) Blimp1-mediated repression of negative regulators is required for osteoclast differentiation. Proc Natl Acad Sci USA 107: 3117-3122.
40. Paicherit C, Coxam V, Bennetau-Pelissero C, Kati-Coulibaly S, Davicco MJ, Lebecque P, Barlet JP (2000) Daidzein is more efficient than genistein in preventing ovariectory-induced bone loss in rats. J Nutr 130: 1675-1681.
41. Pietta PG (2000) Flavonoids as antioxidants. J Nat Prod 63: 1035-1042.
42. Redlich K, Hayer S, Ricci R, David JP, Tohidast-Akrad M, Kollias G, Steiner G, Smolen JS, Wagner EF, Schett G (2002) Osteoclasts are essential for TNF-a-mediated joint destruction. J Clin Invest 110: 1419-1427.
43. Rodan GA, Martin TJ (2000) Therapeutic approaches to bone diseases. Science 289: 1508-1514.
44. Satue M, Arriero Mdel M, Monjo M, Ramis JM (2013) Quercitrin and taxifolin stimulate osteoblast differentiation in MC3T3-E1 cells and inhibit osteoclastogenesis in RAW 264.7 cells. Biochem Pharmacol 86: 1476-1486.
45. Stroup GB, Lark MW, Veber DF, Bhattacharyya A, Blake S, Dare LC, Erhard KF, Hoffman SJ, James IE, Marquis RW, Ru Y, Vasko-Moser JA, Smith BR, Tomaszek T, Gowen M (2001) Potent and selective inhibition of human cathepsin K leads to inhibition of bone resorption in vivo in a nonhuman primate. J Bone Miner Res 16: 1739-1746.
46. Swarnkar G, Sharan K, Siddiqui JA, Mishra JS, Khan K, Khan MP, Gupta V, Rawat P, Maurya R, Dwivedi AK, Sanyal S, Chattopadhyay N (2012) A naturally occurring naringenin derivative exerts potent bone anabolic effects by mimicking oestrogen action on osteoblasts. Br J Pharmacol 165: 1526-1542.
47. Takayanagi H (2007) Osteoimmunology shared mechanisms and crosstalk between the immune and bone systems. Nat Rev Immunol 7: 292-304.
48. Takayanagi H (2007) The role of NFAT in osteoclast formation. Ann N Y Acad Sci 1116: 227-237.
49. Takayanagi H, Kim S, Koga T, Nishina H, Isshiki M, Yoshida H, Saiura A, Isobe M, Yokochi T, Inoue J, Wagner EF, Mak TW, Kodama T, Taniquchi T (2002) Induction and activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signaling in terminal differentiation of osteoclasts. Dev Cell 3: 889-901.
50. Tanaka Y, Nakayamada S, Okada Y (2005) Osteoblasts and osteoclasts in bone remodeling and inflammation. Curr Drug Targets Inflamm Allergy 4: 325-328.
51. Väänänen HK, Zhao H, Mulari M, Halleen JM (2000) The cell biology of osteoclast function. J Cell Sci 113: 377-381.
52. Walsh MC, Choi Y (2014) Biology of the RANKL-RANK-OPG system in immunity, bone, and beyond. Front Immunol 5: 1-11.
53. Walsh MC, Kim N, Kadono Y, Rho J, Lee SY, Lorenzo J, Choi Y (2006) Osteoimmunology: interplay between the immune system and bone metabolism. Annu Rev Immunol 24: 33-63.
54. Wattel A, Kamel S, Mentaverri R, Lorget F, Prouillet C, Petit JP, Farde-lonne P, Brazier M (2003) Biochem Pharmacol. Potent inhibitory effect of naturally occurring flavonoids quercetin and kaempferol on in vitro osteoclastic bone resorption. Biochem Pharmacol 65: 35-42.
55. Wattel A, Kamel S, Prouillet C, Petit JP, Lorget F, Offord E, Brazier M (2004) Flavonoid quercetin decreases osteoclastic differentiation induced by RANKL via a mechanism involving NF kappa B and AP-1. J Cell Biochem 92: 285-295.
56. Winslow MM, Pan M, Starbuck M, Gallo EM, Deng L, Karsenty G, Crab-tree GR (2006) Calcineurin/NFAT signaling in osteoblasts regulates bone mass. Dev Cell 10: 771-782.
57. Wong RW, Rabie AB (2008) Effect of Quercetin on Bone Formation. J Orthop Res 26: 1061-1066.
58. Xu SL, Zhu KY, Bi CW, Yan L, Men SW, Dong TT, Tsim KW (2013) Flavonoids, derived from traditional Chinese medicines, show roles in the differentiation of neurons: possible targets in developing health food products. Birth Defects Res C Embryo Today 99: 292-299.
59. Yagi M, Miyamoto T, Sawatani Y, Iwamoto K, Hosogane N, Fujita N, Morita K, Ninomiya K, Suzuki T, Miyamoto K, Oike Y, Takeya M, Toyama Y, Suda T (2005) DC-STAMP is essential for cell-cell fusion in osteoclasts and foreign body giant cells. J Exp Med 202: 345-351.
60. Yagi M, Ninomiya K, Fujita N, Suzuki T, Iwasaki R, Morita K, Hoso-gane N, Matsuo K, Toyama Y, Suda T, Miyamoto T (2007) Induction of DC-STAMP by alternative activation and downstream signaling mecha-nisms.J Bone Miner Res 22: 992-1001.
61. Yao LH, Jiang YM, Shi J(2004) Flavonoids infood and their health benefits. Plant Foods Human Nutr 59: 113-122.
62. Yeon JT, Choi SW, Park KI, Choi MK, Kim JJ, Youn BS, Lee MS, Oh J (2012) Glutaredoxin2 isoform b (Glrx2b) promotes RANKL-induced osteoclastogenesis through activation of the p38-MAPK signaling pathway. BMB Rep 45: 171-176.
63. Zhao B, Takami M, Yamada A, Wang X, Koga T, Hu X, Tamura T, Ozato K, Choi Y, Ivashkv LB, Takayanagi H, Kamijo R (2009) Interferon regulatory factor-8 regulates bone metabolism by suppressing osteoclas-togenesis. Nat Med 15: 1066-1071.
64. Zhu L, Wei H, Wu Y, Yang S, Xiao L, Zhang J, Peng B (2012) Licorice isoliquiritigenin suppresses RANKL-induced osteoclastogenesis in vitro and prevents inflammatory bone loss in vivo. Int J Biochem Cell Biol 44: 1139-1152.